A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
Latest Information Update: 31 Jan 2023
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms EMBRACE
- Sponsors Amgen; Celgene International SARL
Most Recent Events
- 01 Feb 2023 Primary endpoint (Percentage of Participants Who Achieved a 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 [ Time Frame: Baseline and week 16 ]) has been met, according to Results published in the Journal of the European Academy of Dermatology and Venereology.
- 01 Feb 2023 Results published in the Journal of the European Academy of Dermatology and Venereology
- 30 Aug 2022 According to an Amgen media release, 16-Week Subgroup Analysis will be presented at the 31st European Academy of Dermatology and Venereology (EADV) 2022.